| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
37,011 |
32,698 |
$1.37M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
23,200 |
21,242 |
$1.22M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
20,704 |
19,125 |
$949K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
9,278 |
9,110 |
$802K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
6,901 |
6,748 |
$649K |
| G0315 |
Immunization counseling by a physician or other qualified health care professional for covid-19, ages under 21, 5-15 mins time (this code is used for the medicaid early and periodic screening, diagnostic, and treatment benefit (epsdt) |
17,429 |
13,735 |
$627K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
7,652 |
7,427 |
$613K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
33,901 |
15,792 |
$480K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
32,387 |
13,938 |
$339K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
3,837 |
3,667 |
$297K |
| 99429 |
|
6,744 |
6,539 |
$229K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
1,189 |
1,040 |
$157K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
1,103 |
965 |
$143K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
10,197 |
9,580 |
$143K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
4,698 |
4,483 |
$115K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
933 |
905 |
$78K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
9,222 |
6,864 |
$77K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
725 |
704 |
$65K |
| 99381 |
|
710 |
679 |
$59K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
886 |
861 |
$54K |
| 90461 |
|
5,465 |
4,610 |
$35K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
3,008 |
2,937 |
$35K |
| 97169 |
|
1,339 |
1,323 |
$34K |
| 99001 |
|
5,017 |
4,691 |
$31K |
| 0001A |
|
821 |
799 |
$29K |
| 87807 |
|
2,609 |
2,439 |
$29K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
472 |
450 |
$24K |
| 99383 |
|
229 |
228 |
$22K |
| 0071A |
|
540 |
529 |
$21K |
| 83655 |
|
1,850 |
1,801 |
$21K |
| 0002A |
|
728 |
726 |
$21K |
| 90619 |
|
1,389 |
1,327 |
$18K |
| 0072A |
|
406 |
406 |
$17K |
| 96160 |
|
7,235 |
7,054 |
$17K |
| 90671 |
|
1,015 |
934 |
$16K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
444 |
431 |
$15K |
| 80061 |
Lipid panel |
1,054 |
1,017 |
$12K |
| S8301 |
Infection control supplies, not otherwise specified |
4,455 |
4,148 |
$10K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
107 |
106 |
$10K |
| 83037 |
|
1,131 |
1,087 |
$10K |
| 99382 |
|
101 |
99 |
$10K |
| 90620 |
|
1,796 |
1,743 |
$6K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
463 |
212 |
$4K |
| 90651 |
|
1,913 |
1,875 |
$4K |
| 82947 |
|
1,229 |
1,184 |
$4K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
65 |
65 |
$4K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
72 |
72 |
$3K |
| 81003 |
|
1,597 |
1,480 |
$3K |
| 0054A |
|
61 |
61 |
$2K |
| 0124A |
|
57 |
54 |
$2K |
| 99051 |
|
132 |
128 |
$2K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
175 |
162 |
$2K |
| 90686 |
|
3,820 |
3,803 |
$2K |
| 0004A |
|
33 |
33 |
$1K |
| 0121A |
|
32 |
31 |
$1K |
| 99384 |
|
13 |
13 |
$1K |
| 0151A |
|
28 |
28 |
$1K |
| 90734 |
|
1,144 |
1,143 |
$933.00 |
| 85018 |
|
673 |
653 |
$883.85 |
| 0011A |
|
13 |
13 |
$525.00 |
| 90688 |
|
2,313 |
2,304 |
$475.72 |
| 0052A |
|
12 |
12 |
$439.80 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
96 |
86 |
$379.32 |
| 92015 |
Determination of refractive state |
12 |
12 |
$195.36 |
| 88720 |
|
55 |
28 |
$180.79 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
15 |
15 |
$180.15 |
| 0012A |
|
15 |
14 |
$174.00 |
| 96161 |
|
39 |
39 |
$82.44 |
| 90633 |
|
2,253 |
2,193 |
$75.46 |
| 90715 |
|
1,442 |
1,412 |
$65.08 |
| 91300 |
|
295 |
287 |
$0.01 |
| 90680 |
|
2,310 |
2,244 |
$0.00 |
| 90723 |
|
2,597 |
2,522 |
$0.00 |
| 90647 |
|
3,609 |
3,507 |
$0.00 |
| 90696 |
|
1,086 |
1,064 |
$0.00 |
| 90716 |
|
2,284 |
2,229 |
$0.00 |
| 90700 |
|
1,087 |
1,057 |
$0.00 |
| 90670 |
|
2,580 |
2,558 |
$0.00 |
| 90707 |
|
2,283 |
2,228 |
$0.00 |
| 90713 |
|
25 |
25 |
$0.00 |